Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
SAN DIEGO and TORONTO, Feb. 02, 2017 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer and Gregory Chow, Senior Vice President and Chief Financial Officer, will participate in the upcoming Canaccord Genuity Rare Disease Biopharma 1x1 Day to be held on February 6, 2017 at the InterContinental Barclay Hotel, New York, NY.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Greg Chow, CFO 647-479-9828 [email protected] SMP Communications Susan Pietropaolo 201-923-2049 [email protected]
